HomeMLLCF • OTCMKTS
add
Molecular Partners AG
Nakaraang pagsara
$4.22
Sakop ng taon
$3.85 - $10.14
Market cap
147.29M USD
Average na Volume
44.00
P/E ratio
-
Dividend yield
-
Primary exchange
SWX
Mga balita tungkol sa merkado
Mga Financial
Income Statement
Kita
Net na kita
| (CHF) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | — | — |
Gastos sa pagpapatakbo | 16.14M | 259.35% |
Net na kita | -16.77M | -48.09% |
Net profit margin | — | — |
Kita sa bawat share | -0.45 | — |
EBITDA | -15.59M | -2.21% |
Aktuwal na % ng binabayarang buwis | 0.01% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (CHF) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 130.91M | -24.82% |
Kabuuang asset | 141.10M | -23.98% |
Kabuuang sagutin | 12.90M | -24.36% |
Kabuuang equity | 128.19M | — |
Natitirang share | 37.27M | — |
Presyo para makapag-book | 1.23 | — |
Return on assets | -26.94% | — |
Return on capital | -29.41% | — |
Cash Flow
Net change in cash
| (CHF) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -16.77M | -48.09% |
Cash mula sa mga operasyon | -17.08M | -0.18% |
Cash mula sa pag-invest | 34.96M | 98.53% |
Cash mula sa financing | -302.00K | -0.67% |
Net change in cash | 17.50M | 1,588.90% |
Malayang cash flow | -13.72M | -22.38% |
Tungkol
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Itinatag
2004
Website
Mga Empleyado
159
